Formulation of a Positively Charged Testosterone Niosome-Loaded Hydrogel: Optimization, IVIVC Correlation, and pharmacokinetic evaluation

The present study deals with the formulation of a hydrogel based on the positively charged niosomes for the delivery of testosterone at an improved skin permeation rate and offering sustained release. Testosterone-loaded niosomes (F1, F2, F3) were prepared with different concentrations of an octadecyl amine as a positive charge inducer combined with Span 60, Tween 60, and cholesterol; subsequently, these were incorporated into a hydrogel matrix of xanthan gum, iota carrageenan, and hyaluronic acid. Characterization confirmed stability, encapsulation efficiency, and diffusion-controlled drug release for each formulation. In vitro, ex vivo, and in vivo pharmacokinetic studies demonstrated that formulation H3, with the highest concentration of octadecyl amine, achieved maximum release and systemic absorption compared to H1, H2, and the marketed Androgel reference. Strong IVIVC correlation supports the potential of niosome-based hydrogel for the transdermal delivery of testosterone and that HF provided an optimized and sustained release of the hormone for clinical applications in hormone replacement therapy.

Authors

Publication Details

Journal
Acta Poloniae Pharmaceutica - Drug Research
Published
2025-06-24
DOI
https://doi.org/10.32383/appdr/203414
Primary Topic
Hormonal and reproductive studies
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Formulation of a Positively Charged Testosterone Niosome-Loaded Hydrogel: Optimization, IVIVC Correlation, and pharmacokinetic evaluation

Yi Ge, Mohammed Aljuaid, Roy Rillera Marzo, Saeid Mezail Mawazi et al.
1 links
Acta Poloniae Pharmaceutica - Drug Research
Hormonal and reproductive studies
article

Formulation of a Positively Charged Testosterone Niosome-Loaded Hydrogel: Optimization, IVIVC Correlation, and pharmacokinetic evaluation

Yi Ge, Mohammed Aljuaid, Roy Rillera Marzo, Saeid Mezail Mawazi, Riyanto Teguh Widodo, Nausneen Fathima
article en

Abstract

The present study deals with the formulation of a hydrogel based on the positively charged niosomes for the delivery of testosterone at an improved skin permeation rate and offering sustained release. Testosterone-loaded niosomes (F1, F2, F3) were prepared with different concentrations of an octadecyl amine as a positive charge inducer combined with Span 60, Tween 60, and cholesterol; subsequently, these were incorporated into a hydrogel matrix of xanthan gum, iota carrageenan, and hyaluronic acid. Characterization confirmed stability, encapsulation efficiency, and diffusion-controlled drug release for each formulation. In vitro, ex vivo, and in vivo pharmacokinetic studies demonstrated that formulation H3, with the highest concentration of octadecyl amine, achieved maximum release and systemic absorption compared to H1, H2, and the marketed Androgel reference. Strong IVIVC correlation supports the potential of niosome-based hydrogel for the transdermal delivery of testosterone and that HF provided an optimized and sustained release of the hormone for clinical applications in hormone replacement therapy.

Acta Poloniae Pharmaceutica - Drug ResearchVol. 82(1)
King Saud University
Openalex Percentile: Top 78%
Hormonal and reproductive studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Formulation of a Positively Charged Testosterone Niosome-Loaded Hydrogel: Optimization, IVIVC Correlation, and pharmacokinetic evaluation — Yi Ge, Mohammed Aljuaid, et al. · Acta Poloniae Pharmaceutica - Drug Research (2025) | TGRS Research Map | TGRS